The effects of old, new and emerging medicines on metabolic aberrations in PCOS
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age that is associated with significant adverse short- and long-term health consequences. Multiple metabolic aberrations, such as insulin resistance (IR) and hyperinsulinaemia, high incidence of impaired glucose tolerance, visceral obesity, inflammation and endothelial dysfunction, hypertension and dyslipidemia are associated with the syndrome. Assessing the metabolic aberrations and their long term health impact in women with PCOS is challenging and becomes more important as therapeutic interventions currently available for the management of PCOS are not fully able to deal with all these consequences. Current therapeutic management of PCOS has incorporated new treatments resulting from the better understanding of the pathophysiology of the syndrome. The aim of this review is to summarize the effect of old, new and emerging therapies used in the management of PCOS, on the metabolic aberrations of PCOS
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449 · cited 1×
“Their benefit on reduction of cardiovascular morbidity and mortality in primary and secondary prevention trials is well proven [Downs et al. 1998; Anon, 1994; Sacks et al. 1996; Shepherd et al. 1995].”
BackgroundSacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · cited 2×
“Their benefit on reduction of cardiovascular morbidity and mortality in primary and secondary prevention trials is well proven [Downs et al. 1998; Anon, 1994; Sacks et al. 1996; Shepherd et al. 1995].”
BackgroundDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“Rosiglitazone was also suspended recently from the European market (September, 2010) due to its association to increased cardiovascular mortality [Nissen and Wolski, 2007] and the FDA in USA has decide that rosiglitazone could be obtained only under a very stringent restricted program.”
BackgroundUnconventional medicine in the United States-Prevalence, costs, and patterns of use
Eisenberg, D. M., Kessler, R. C., Foster, C., Norlock, F. E., Calkins, D. R., & Delbanco, T. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301283280406 · Cited by 4,177 · cited 2×
“AGE-low diet Women with PCOS are at increased atherogenic risk and endogenous AGEs seem to play a significant role [Chen et al. 2008; Dvorak and Vrzal, 2011; Eisenberg et al. 1993; Eyvazzadeh et al. 2009].”
BackgroundProfound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Teede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1045 · Cited by 931
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786 · cited 4×
“A metanalysis of 13 controlled trials in women with PCOS concluded that metformin is potent in the reduction of fasting insulin levels [Lord et al. 2003].”
BackgroundInfluentialAdvanced glycoxidation end products in commonly consumed foods
Goldberg, T., Cai, W., Peppa, M., Dardaine, V., Baliga, B. S., Uribarri, J., & Vlassara, H. (2004) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2004.05.214 · Cited by 744 · cited 1×
“COC can induce systolic hypertension and is thus contraindicated in hypertensive women with PCOS and should be discontinued if systolic hypertension develops [Goldenberg et al. 2003].”
BackgroundVlassara, H., Cai, W., Crandall, J., Goldberg, T., Oberstein, R., Dardaine, V., Peppa, M., & Rayfield, E. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242407999 · Cited by 668 · cited 1×
“Studies in animal and humans with diabetes indicated that dietary AGE restriction results in significant reduction of circulating AGE levels and prevents progression of atherosclerosis [Hofmann et al. 2002; Uribarri et al. 2003; Vlassara et al. 2002].”
Pasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G. E., Filicori, M., & Morselli-Labate, A. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6738 · Cited by 635 · cited 1×
“…of longer duration where metformin was combined with lifestyle interventions have demonstrated a significant reduction in visceral fat mass [Gambineri et al. 2006; Gambineri et al. 2004; Pasquali et al. 2000; Tang et al. 2006] and this effect also seemed to be dose dependent [Bruno et al. 2007].”
BackgroundPrevalence and predictors of dyslipidemia in women with polycystic ovary syndrome
Legro, R. S., Kunselman, A. R., & Dunaif, A. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00948-2 · Cited by 622
DeUgarte, C. M., Bartolucci, A. A., & Azziz, R. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.070 · Cited by 589 · cited 1×
“Insulin resistance is present in 60-80% of women with PCOS, with a higher prevalence observed in those who are obese [Carmina and Lobo, 2004; DeUgarte et al. 2005].”
BackgroundMenstrual cycle irregularity and risk for future cardiovascular disease
Solomon, C. G., Hu, F. B., Dunaif, A., Rich-Edwards, J. E., Stampfer, M. J., Willett, W. C., Speizer, F. E., & Manson, J. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8471 · Cited by 528 · cited 1×
“Up to 35-40% of women with PCOS have IGT and 10% develop T2DM during the third or fourth decade [Ehrmann et al. 1999; Legro et al. 1999; Solomon et al. 2002].”
BackgroundMortality of Women with Polycystic Ovary Syndrome at Long-term Follow-up
Pierpoint, T., McKeigue, P. M., Isaacs, A. J., Wild, S. H., & Jacobs, H. S. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00035-3 · Cited by 504 · cited 2×
“…of cardiovascular events in premenopausal women with http://tae.sagepub.com 29 PCOS is limited and, despite the multitude of cardiovascular risk factors associated with PCOS, increased mortality due to cardiovascular disease has not been demonstrated [Pierpoint et al. 1998; Wild et al. 2000].”
BackgroundEhrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426 · cited 5×
“Metformin also ameliorates lipid profile via various mechanisms [Diamanti-Kandarakis et al. 1998; Palomba et al. 2009; Viollet et al. 2006], and directly inhibits thecal androgen production [Attia, et al.”
BackgroundMethodInfluentialScreening for Abnormal Glucose Tolerance in Adolescents with Polycystic Ovary Syndrome
Palmert, M. R., Gordon, C. M., Kartashov, A. I., Legro, R. S., Emans, S. J., & Dunaif, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8305 · Cited by 354 · cited 1×
“In another study supplementation of folate increased the effect of metformin on the vascular endothelium in women with PCOS, but the mechanism remains unknown [Palomba et al. 2010].”
BackgroundTang, T., Glanville, J., Hayden, C. J., White, D., Barth, J. H., & Balen, A. H. (2006) · Human Reproduction · doi:10.1093/humrep/dei311 · Cited by 335
Metformin for the treatment of the polycystic ovary syndrome
Nestler, J. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0707092 · Cited by 313
Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications
Diamanti-Kandarakis, E. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000598 · Cited by 294 · cited 4×
“However, studies have shown no effect on lipid profile in women with PCOS on OC [Diamanti-Kandarakis, 2008; Pasquali et al. 1999].”
BackgroundInfluentialSelf-citationHoeger, K., Davidson, K., Kochman, L., Cherry, T., Kopin, L., & Guzick, D. S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0461 · Cited by 256
Gambineri, A., Patton, L., Vaccina, A., Cacciari, M., Morselli-Labate, A. M., Cavazza, C., Pagotto, U., & Pasquali, R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2250 · Cited by 221 · cited 3×
“Studies of longer duration where metformin was combined with lifestyle interventions have demonstrated a significant reduction in visceral fat mass [Gambineri et al. 2006; Gambineri et al. 2004; Pasquali et al. 2000; Tang et al. 2006] and this effect also seemed to be dose dependent [Bruno et al.…”
BackgroundGambineri, A., Pelusi, C., Genghini, S., Morselli‐Labate, A. M., Cacciari, M., Pagotto, U., & Pasquali, R. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.01973.x · Cited by 216 · cited 2×
“…of longer duration where metformin was combined with lifestyle interventions have demonstrated a significant reduction in visceral fat mass [Gambineri et al. 2006; Gambineri et al. 2004; Pasquali et al. 2000; Tang et al. 2006] and this effect also seemed to be dose dependent [Bruno et al. 2007].”
BackgroundCentral Role of the Adipocyte in the Metabolic Syndrome
Bergman, R. N., Van Citters, G. W., Mittelman, S. D., Dea, M. K., Hamilton-Wessler, M., Kim, S. P., & Ellmerer, M. (2001) · Journal of Investigative Medicine · doi:10.2310/6650.2001.34108 · Cited by 202
He, C., Sabol, J., Mitsuhashi, T., & Vlassara, H. (1999) · Diabetes · doi:10.2337/diabetes.48.6.1308 · Cited by 191
Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus
Lopez, L. M., Grimes, D. A., & Schulz, K. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006133.pub5 · Cited by 166 · cited 2×
“However, follow-up studies demonstrated a limited effect on metabolic risk with no clinical significant repercussions when low doses of COCs were used [Gaspard et al. 2003; Lopez et al. 2007].”
BackgroundMethodBanaszewska, B., Pawelczyk, L., Spaczynski, R. Z., Dziura, J., & Duleba, A. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1988 · Cited by 143
Metabolic effects of oral contraceptives in women with polycystic ovary syndrome.
Korytkowski, M. T., Mokan, M., Horwitz, M. J., & Berga, S. L. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.11.7593446 · Cited by 140 · cited 2×
“1990; Vrbíková and Cibula, 2005] or may have no effect at all [Korytkowski et al. 1995; Pasquali et al. 1999].”
BackgroundMastorakos, G., Koliopoulos, C., & Creatsas, G. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)02993-x · Cited by 137
Evidence of proatherogenic inflammation in polycystic ovary syndrome
González, F., Rote, N. S., Minium, J., & Kirwan, J. P. (2009) · Metabolism · doi:10.1016/j.metabol.2009.02.022 · Cited by 135 · cited 6×
“In general the available literature indicates that OCs may increase LDL-cholesterol and total cholesterol and increase HDLcholesterol [Cibula, et al. 2005; Falsetti and Pasinetti, 1995; Guido et al. 2004; Harborne et al. 2003; Hoeger et al. 2008; Lemay et al. 2006; Luque-Ramírez et al. 2007; Mastorakos et al. 2002; Mo…”
BackgroundInfluentialBerneis, K., Rizzo, M., Lazzaroni, V., Fruzzetti, F., & Carmina, E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1705 · Cited by 121 · cited 2×
“OCs and lipids The most common lipid alterations observed in women with PCOS are increased TG levels and decreased HDL cholesterol levels, with increases in total cholesterol and LDL cholesterol being more rare [Berneis et al. 2007].”
BackgroundLord, J., Thomas, R., Fox, B., Acharya, U., & Wilkin, T. (2006) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.00966.x · Cited by 113
Indices of low-grade inflammation in polycystic ovary syndrome
DIAMANTI‐KANDARAKIS, E., PATERAKIS, T., & KANDARAKIS, H. A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1365.015 · Cited by 112
Self-citationNader, S., & Diamanti-Kandarakis, E. (2007) · Human Reproduction · doi:10.1093/humrep/del407 · Cited by 109
Self-citationGaspard, U., Scheen, A., Endrikat, J., Buicu, C., Lefebvre, P., Gerlinger, C., & Heithecker, R. (2003) · Contraception · doi:10.1016/s0010-7824(02)00537-1 · Cited by 72
Metabolic abnormalities in visceral obesity
Björntorp, P. (1992) · Annals of Medicine · doi:10.3109/07853899209164137 · Cited by 50 · cited 1×
“Compared with peripheral fat, central fat is insulin resistant and recycles fatty acids more rapidly through lipolysis [Bergman et al. 2001; Björntorp, 1992; Steven et al. 2002].”
BackgroundSharma, S. T., Wickham, E. P., & Nestler, J. E. (2007) · Endocrine Practice · doi:10.4158/ep.13.4.373 · Cited by 49 · cited 2×
“4% versus 16-19%) and none of the women, even those with IGT at the base line, developed diabetes [Sharma et al. 2007].”
Background
Cited by
Epidemiology, diagnosis, and management of polycystic ovary syndrome
Sirmans, S., & Pate, K. (2013) · Clinical Epidemiology · doi:10.2147/clep.s37559 · Cited by 1,302
Fruzzetti, F., Perini, D., Russo, M., Bucci, F., & Gadducci, A. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1236078 · Cited by 135
“metformin may be limited by gastrointestinal side effects [15,16].”
BackgroundAsemi, Z., & Esmaillzadeh, A. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0034-1376990 · Cited by 134
“Insulin resistance and elevated inflammatory factors in women with PCOS can result in several complications [9, 10].”
Xing, C., Zhang, J., Zhao, H., & He, B. (2022) · International Journal of Women's Health · doi:10.2147/ijwh.s344542 · Cited by 118
Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540578 · Cited by 94
“Existing evidence shows that MET may have metabolic and reproductive benefits, including weight reduction, decreasing IR, and androgen levels, besides restoration of normal menstrual cyclicity and ovulation [6, 7].”
Background
Metadata
- Authors
- Bargiota, A., & Diamanti-Kandarakis, E.
- Venue
- Therapeutic Advances in Endocrinology and Metabolism
- Publisher
- SAGE Publications
- Published
- 2012-02
- Volume
- 3
- Issue
- 1
- Pages
- 27-47
- ISSN
- 2042-0188 (ISSN-L)
- 2042-0196
- OpenAlex
- W2077929133
- Cited by
- 119
- References
- 41
- FWCI
- 10.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.